These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30837032)

  • 1. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
    Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
    Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.
    Zhang Y; Liu Q; Wei W; Zhang G; Yan S; Dai R; Sun Y; Su D; Lv S; Xia Y; Li J; Li C
    BMC Cancer; 2021 Oct; 21(1):1101. PubMed ID: 34645397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyphyllin I induces cell cycle arrest and apoptosis in human myeloma cells via modulating β-catenin signaling pathway.
    Liang Y; Li X; He X; Qiu X; Jin XL; Zhao XY; Xu RZ
    Eur J Haematol; 2016 Oct; 97(4):371-8. PubMed ID: 26821882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Weniger MA; Overbey J; Dunleavy K; Wilson WH; Wiestner A; Parekh S
    Oncotarget; 2015 Sep; 6(29):27332-42. PubMed ID: 25714012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation.
    Choi PJ; O Y; Her JH; Yun E; Song GY; Oh S
    Leuk Res; 2017 Sep; 60():103-108. PubMed ID: 28772205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.
    Lee Y; Jung JI; Park KY; Kim SA; Kim J
    Oncotarget; 2017 Jun; 8(25):41091-41101. PubMed ID: 28467797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
    Zeng D; Liu M; Pan J
    Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
    Qiang YW; Hu B; Chen Y; Zhong Y; Shi B; Barlogie B; Shaughnessy JD
    Blood; 2009 Apr; 113(18):4319-30. PubMed ID: 19196662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway.
    Qiu X; Wu X; He W
    Adv Clin Exp Med; 2022 Jul; 31(7):789-794. PubMed ID: 35394126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
    Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
    Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
    PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
    Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/β-catenin signal pathway in a renal cell carcinoma cell line.
    Konac E; Varol N; Yilmaz A; Menevse S; Sozen S
    Exp Biol Med (Maywood); 2013 Sep; 238(9):1009-16. PubMed ID: 23975733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
    Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
    Sukhdeo K; Mani M; Zhang Y; Dutta J; Yasui H; Rooney MD; Carrasco DE; Zheng M; He H; Tai YT; Mitsiades C; Anderson KC; Carrasco DR
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7516-21. PubMed ID: 17452641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ilimaquinone and ethylsmenoquinone, marine sponge metabolites, suppress the proliferation of multiple myeloma cells by down-regulating the level of β-catenin.
    Park S; Yun E; Hwang IH; Yoon S; Kim DE; Kim JS; Na M; Song GY; Oh S
    Mar Drugs; 2014 May; 12(6):3231-44. PubMed ID: 24879546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
    Schmeel FC; Schmeel LC; Kim Y; Schmidt-Wolf IG
    Hematol Oncol; 2014 Dec; 32(4):197-204. PubMed ID: 24470348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
    Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
    Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
    Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
    Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.